Purpose: To investigate the antimicrobial efficacy of a novel amphibian antimicrobial peptide, Esculentin1-21 (Esc1-21), in vitro and in a murine model of Pseudomonas aeruginosa (PA) keratitis. Methods: Standard cfu assays were used to determine the MIC of Esc1-21 against PA strains ATCC 27853 and 19660. The effects of physiological salt concentrations and tears (basal and reflex) on antipseudomonal activity were also tested. MTT assays were performed to determine if Esc1-21 was toxic to a human corneal epithelial cell line (HCEC). For in vivo studies corneas of C57BL/6 mice were scratched; then 105-106 cfu PA ATCC19660 applied topically. Esc1-21 (40 μM) or PBS was applied topically three times/day for up to 5 days (pi) post-infection. At 1, 3 and 5 days pi, severity of infection was graded by slit-lamp, neutrophil infiltration was assessed by MPO assay and viable bacterial counts were determined. Results: The MIC for Esc1-21 was 4 μM and 32 μM for ATCC 27853 and 19660 (n=3) respective
Esc1-21 a Novel Antimicrobial Peptide for Microbial Keratitis / Satya Sree N., Kolar; Hasna, Baidouri; Luca, Vincenzo; Giuseppe, Mannino; Mangoni, Maria Luisa; Alison M., Mcdermott. - ELETTRONICO. - (2014). (Intervento presentato al convegno Annual Meting Association for Research in Vision and Ophtalmology tenutosi a Orlando nel May 4-8, 2014).
Esc1-21 a Novel Antimicrobial Peptide for Microbial Keratitis
LUCA, VINCENZO;MANGONI, Maria Luisa;
2014
Abstract
Purpose: To investigate the antimicrobial efficacy of a novel amphibian antimicrobial peptide, Esculentin1-21 (Esc1-21), in vitro and in a murine model of Pseudomonas aeruginosa (PA) keratitis. Methods: Standard cfu assays were used to determine the MIC of Esc1-21 against PA strains ATCC 27853 and 19660. The effects of physiological salt concentrations and tears (basal and reflex) on antipseudomonal activity were also tested. MTT assays were performed to determine if Esc1-21 was toxic to a human corneal epithelial cell line (HCEC). For in vivo studies corneas of C57BL/6 mice were scratched; then 105-106 cfu PA ATCC19660 applied topically. Esc1-21 (40 μM) or PBS was applied topically three times/day for up to 5 days (pi) post-infection. At 1, 3 and 5 days pi, severity of infection was graded by slit-lamp, neutrophil infiltration was assessed by MPO assay and viable bacterial counts were determined. Results: The MIC for Esc1-21 was 4 μM and 32 μM for ATCC 27853 and 19660 (n=3) respectiveI documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
